New combo therapy targets rare, aggressive lung cancer

NCT ID NCT07476287

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Mar 17, 2026 · Last updated Apr 24, 2026 · Updated 5 times

Summary

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive lung cancer. Participants must be 18 or older, have T-SCLC that hasn't been treated yet, and have had a prior EGFR-mutated lung cancer. The goal is to see if the combination shrinks tumors and how safe it is.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hope and Healing Clinical Research
RECRUITING

Hinsdale, Illinois, 60521, United States
Hope and Healing Clinical Research
RECRUITING

New Lenox, Illinois, 60451, United States
Japanese Foundation for Cancer Research
NOT_YET_RECRUITING

Kotoku, Tokyo, 135-8550, Japan

Conditions

Explore the condition pages connected to this study.

CARCINOMA, SMALL CELL LUNG LUNG NEOPLASMS SMALL CELL CANCER OF THE LUNG SMALL CELL LUNG CANCER SMALL CELL LUNG CANCER (SCLC) TRANSFORMED SMALL CELL LUNG CANCER